Drug Profile
ACU D1
Alternative Names: ACU-D1Latest Information Update: 05 Feb 2024
Price :
$50
*
At a glance
- Originator Emory University
- Developer Accuitis; Emory University; Mercer University
- Class
- Mechanism of Action NF-kappa B inhibitors; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rosacea
- No development reported Psoriasis
Most Recent Events
- 05 Feb 2024 Emory University plans a phase I trial for HIV infections in USA in March 2024 (Topical) (NCT06233331)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Rosacea in USA (Topical)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Psoriasis in USA (Topical)